

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**PART I**

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER, 2012**

	Unaudited				Audited	
	3 months ended 30.09.2012	Preceding 3 months ended 30.06.2012	Corresponding 3 months ended 30.09.2011	9 months ended 30.09.2012	9 months ended 30.09.2011	Year ended 31.12.2011
Income from Operations						
Net Sales (net of excise duty)	66850	65196	60756	194324	177200	233803
Other Operating Income (net of expenses relating to service income)	749	990	706	2446	2628	3785
Total Income from Operations (net)	67599	66186	61462	196770	179828	237588
Expenses						
Cost of materials consumed	14018	10350	12298	34510	33672	43123
Purchases of stock-in-trade	16121	14770	14314	43242	41539	53337
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1672)	1954	(2414)	4001	(7589)	(5609)
Total materials consumed	28467	27074	24198	81753	67622	90851
Employee benefits expense	7471	7886	6609	21857	20813	27836
Depreciation	484	430	490	1326	1426	2041
Other expenses	12067	11288	13395	34200	34281	44761
Expenses relating to service income	(1046)	(1330)	(1044)	(3228)	(2907)	(4098)
Total operating expenses	18976	18274	19450	54155	53613	70540
Total expenses	47443	45348	43648	135908	121235	161391
Profit from Operations before Other Income and Exceptional Items	20156	20838	17814	60862	58593	76197
Other Income	4038	3802	3706	15174	11797	15962
Profit from ordinary activities before Exceptional Items	24194	24640	21520	76036	70390	92159
Exceptional Items	(1655)	(901)	(19)	(11853)	(30679)	(32254)
Profit from ordinary activities before tax	22539	23739	21501	64183	39711	59905
Tax Expense						
Tax on Profit from ordinary activities before Exceptional Items	7833	7678	6921	24144	21992	29023
Tax relating to Exceptional Items	(528)	(291)	(6)	(3836)	(11667)	(12178)
Total Tax Expense	7305	7387	6915	20308	10325	16845
Net Profit from ordinary activities	15234	16352	14586	43875	29386	43060
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470	8470	8470	8470
Reserves excluding Revaluation Reserves						183523
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)						
Basic and diluted EPS (Rs.)	18.0	19.3	17.2	51.8	34.7	50.8

**PART II**

**A. PARTICULARS OF SHAREHOLDING**

Public Shareholding						
Number of shares	41785529	41785529	41785529	41785529	41785529	41785529
Percentage of shareholding	49.3%	49.3%	49.3%	49.3%	49.3%	49.3%
Promoters and promoter group Shareholding						
(a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
(b) Non-encumbered						
- Number of shares	42917488	42917488	42917488	42917488	42917488	42917488
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	50.7%	50.7%	50.7%	50.7%	50.7%	50.7%

Particulars	3 months ended 30.09.2012
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	-
Received during the quarter	9
Disposed of during the quarter	9
Remaining unresolved at the end of the quarter	-

- Net Sales of the Pharmaceuticals business grew by 11.1% during the quarter ended 30th September, 2012, as compared to the corresponding quarter in the previous year.
- Exceptional Items for the three months ended 30th September, 2012 mainly pertain to rationalisation initiatives relating to a manufacturing site.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 9th November, 2012.
- The statutory auditors have carried out a limited review of the standalone results for the quarter ended 30th September 2012.
- The figures for 2011 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

Dr. Hasit B. Joshipura  
Managing Director

9th November, 2012